Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 14Lymphoma 12Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 7Neoplasms 4Lymphoma, B-Cell 4Burkitt Lymphoma 4Recurrence 3Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasm, Residual 1Melanoma 1Mature B-cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Heart Failure 1Extensive Stage Small Cell Lung Cancer 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

entrectinib 2atezolizumab 2alectinib 2venetoclax 1pertuzumab 1obinutuzumab 1ibrutinib 1etoposide phosphate 1enzalutamide 1cobimetinib 1capmatinib 1acalabrutinib 1Vincristine 1Vemurafenib 1Trastuzumab 1Specimen Handling 1Rituximab 1Radiotherapy 1Prednisone 1Positron-Emission Tomography 1Nivolumab 1Genetic Testing 1Genetic Counseling 1Follow-Up Studies 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Chromatin Immunoprecipitation Sequencing 1CA-4948 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoproliferative Disorders × obinutuzumab × Clear all
NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Emory University

Phase 2 Recruiting
49 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡